US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with ...

Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable ...

Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.

“Bemarituzumab is the first FGFR2b inhibitor to demonstrate a statistically and clinically significant overall survival benefit in a randomized Phase 3 trial for the first-line treatment of ...

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...

Wall Street optimistic for July 4 weekend, sees opportunities in Freeport-McMoRan, Honeywell, Caterpillar, and Amgen.